Jonathan H. Kaufman - 19 Dec 2022 Form 3 Insider Report for LIPELLA PHARMACEUTICALS INC (LIPO)

Role
President, Chief Executive Officer, Secretary, Treasurer, and Chairman of the Board of Directors, Director, 10%+ Owner
Signature
/s/ Jonathan H Kaufman
Issuer symbol
LIPO
Transactions as of
19 Dec 2022
Transactions value $
$0
Form type
3
Filing time
20 Dec 2022, 20:48:16 UTC
Next filing
21 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LIPO Common Stock 688,941 19 Dec 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LIPO Stock Options 19 Dec 2022 Common Stock 80,000 $1.25 Direct F1
holding LIPO Stock Options 19 Dec 2022 Common Stock 200,000 $1.25 Direct F2
holding LIPO Stock Options 19 Dec 2022 Common Stock 100,000 $1.25 Direct F3
holding LIPO Stock Options 19 Dec 2022 Common Stock 100,000 $5 Direct F4
holding LIPO Stock Options 19 Dec 2022 Common Stock 160,000 $5 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Number of shares of Common Stock beneficially owned consists of 80,000 shares of Common Stock issuable upon the exercise of stock options held by the Reporting Person, which are exercisable for shares of Common Stock at a price of $1.25 per share.
F2 Number of shares of Common Stock beneficially owned consists of 200,000 shares of Common Stock issuable upon the exercise of stock options held by the Reporting Person, which are exercisable for shares of Common Stock at a price of $1.25 per share.
F3 Number of shares of Common Stock beneficially owned consists of 100,000 shares of Common Stock issuable upon the exercise of stock options held by the Reporting Person, which are exercisable for shares of Common Stock at a price of $1.25 per share.
F4 Number of shares of Common Stock beneficially owned consists of 100,000 shares of Common Stock issuable upon the exercise of stock options held by the Reporting Person, which are exercisable for shares of Common Stock at a price of $5.00 per share. The option became exercisable as to one-third of the shares on March 31, 2022, and will become exercisable as to one-third of the shares on March 31, 2023 and the remaining one-third of the shares on March 31, 2024.
F5 Number of shares of Common Stock beneficially owned consists of 160,000 shares of Common Stock issuable upon the exercise of stock options held by the Reporting Person, which are exercisable for shares of Common Stock at a price of $5.00 per share. The option became exercisable as to one-third of the shares on September 3, 2022, and will become exercisable as to one-third of the shares on September 3, 2023 and the remaining one-third of the shares on September 3, 2024.

Remarks:

President, Chief Executive Officer, Secretary, Treasurer, and Chairman of the Board of Directors